ReviewMedical gas research2027
Molecular hydrogen and osteoarthritis: multi-target mechanisms and therapeutic effectiveness.
Review in Medical gas research, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis is a prevalent degenerative joint disease characterized by a self-perpetuating cycle of chronic inflammation, oxidative stress, and extracellular matrix degradation. Current therapies provide only symptomatic relief and do not alter disease progression, highlighting the urgent need for effective disease-modifying osteoarthritis drugs. Molecular hydrogen has emerged as a promising therapeutic candidate due to its unique selective antioxidant, anti-inflammatory, and anti-apoptotic properties. This review summarizes the multi-target mechanisms of molecular hydrogen and highlights innovative delivery technologies designed to overcome its key pharmacokinetic limitations, especially rapid diffusion and short residence time in the joint. We critically evaluate advanced strategies ranging from sustained-release injectable depots to stimulus-responsive nanocarriers and cell-based delivery systems. Clinical translation remains at an early stage; progress will depend on integrating intelligent, localized delivery systems with rigorously designed clinical trials to validate molecular hydrogen as a safe and effective disease-modifying osteoarthritis drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.